Search
for
Sort by
Research 331–360 of 1000+
- Alopecia areata
- Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis
- 43647 Treatment of Refractory Folliculitis Decalvans with the Topical JAK Inhibitor Tofacitinib
- PSS20 MEDIATION MODELING AND MEASUREMENT CHARACTERISTICS OF THE ITCH SEVERITY SCORE FROM A PHASE 2B TRIAL OF ORAL CP-690-550 IN PATIENTS WITH MODERATE TO-SEVERE PLAQUE PSORIASIS
- Infectious events in patients with alopecia areata treated with JAK inhibitors: low burden and minimal impact on persistence in treatment
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- Efficacy and Safety of Ritlecitinib in Alopecia Areata: A Systematic Review and Meta-Analysis (Preprint)
- Alopecia universalis following human papillomavirus vaccine administration: a case report
- Evaluating Scarring Alopecia Therapies from the Patient Perspective: Knowledge, Barriers to Care, and Treatment Satisfaction
- Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
- Observation and consideration on using of JAKi in clinical trials in times of COVID ‐19
- The Role of Janus Kinase Inhibitors in Dermatology
- Efficacy of Janus kinase inhibitors in adult patients with alopecia areata
- Medicaid coverage of Janus kinase inhibitors for alopecia areata treatment
- Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
- Janus Kinase inhibitors in dermatology: a review
- P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
- Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib
- Targeted immunotherapy for hair regrowth and regeneration
- Refractory alopecia universalis associated with dermatomyositis successfully treated with tofacitinib
- Janus Kinase Inhibitors in Dermatology: Part 1 — General Considerations and Applications in Vitiligo and Alopecia Areata
- The Current State of Patient Adherence to Lab Monitoring Guidelines for Janus Kinase Inhibitors in Patients with Alopecia Areata.
- Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
- A review of Janus kinase inhibitor use in scarring alopecia
- Inibidores das Janus Associated Kinases na Terapêutica Farmacológica
- Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
- Relapse of alopecia areata during ongoing Janus kinase inhibitor therapy is not uncommon and usually occurs in previously affected areas: A multicenter Italian real-world study
- Real-world Effectiveness and Safety of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study of 72 Patients
- Dermatologic Comorbidities Associated with Atopic Dermatitis Towards a Shared Therapeutical Approach: A Narrative Review
- Current Trends and Emerging Paradigms in the Treatment of Alopecia Areata